Porton Pharma Solutions announced that its Chongqing Changshou plant underwent a cGMP site inspection by the US Food and Drug Administration (FDA) from March 25th to 29th, 2024. The inspection covered quality, production, material management, and laboratory controls. Recently, the company received an Establishment Inspection Report (EIR) from the FDA, and the site inspection passed with zero defects ("0-483") .
博腾股份：重庆长寿工厂通过美国FDA现场检查
Porton Pharma Solutions: Chongqing Changshou factory passes on-site inspection by the US FDA.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated